HitGen Inc
SSE:688222

Watchlist Manager
HitGen Inc Logo
HitGen Inc
SSE:688222
Watchlist
Price: 12.07 CNY -7.08% Market Closed
Market Cap: 4.8B CNY
Have any thoughts about
HitGen Inc?
Write Note

HitGen Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

HitGen Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
HitGen Inc
SSE:688222
Cash from Operating Activities
ÂĄ125.2m
CAGR 3-Years
328%
CAGR 5-Years
20%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Cash from Operating Activities
ÂĄ12.8B
CAGR 3-Years
40%
CAGR 5-Years
43%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Cash from Operating Activities
ÂĄ2.6B
CAGR 3-Years
11%
CAGR 5-Years
24%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Cash from Operating Activities
ÂĄ3.2B
CAGR 3-Years
13%
CAGR 5-Years
30%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Cash from Operating Activities
ÂĄ1.1B
CAGR 3-Years
-4%
CAGR 5-Years
15%
CAGR 10-Years
37%
W
WuXi XDC Cayman Inc
HKEX:2268
Cash from Operating Activities
ÂĄ332.8m
CAGR 3-Years
262%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

HitGen Inc
Glance View

Market Cap
4.8B CNY
Industry
Life Sciences Tools & Services

HitGen, Inc. engages in the provision deoxyribonucleic acid encoded compound library (DEL) for research and development of seed and lead compounds. The company is headquartered in Chengdu, Sichuan and currently employs 508 full-time employees. The company went IPO on 2020-04-16. The firm focuses on the research and creation of deoxyribonucleic acid encoded compound library (DEL) technology, research and development of hit compounds and lead compounds. The firm mainly provides DEL screening services, DEL library customization services, chemical synthesis services and transfer of new drug research and development projects. The firm conducts its businesses within the domestic market and to overseas markets.

Intrinsic Value
7.23 CNY
Overvaluation 40%
Intrinsic Value
Price

See Also

What is HitGen Inc's Cash from Operating Activities?
Cash from Operating Activities
125.2m CNY

Based on the financial report for Dec 31, 2023, HitGen Inc's Cash from Operating Activities amounts to 125.2m CNY.

What is HitGen Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
20%

Over the last year, the Cash from Operating Activities growth was 137%. The average annual Cash from Operating Activities growth rates for HitGen Inc have been 328% over the past three years , 20% over the past five years .

Back to Top